CLOs on the Move

Motus GI

www.motusgi.com

 
Motus GI Holdings, Inc. (NASDAQ: MOTS) is a medical technology company based in the U.S., with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System, designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.motusgi.com
  • 1301 E. Broward Blvd. Suite 310
    Fort Lauderdale, FL USA 33301
  • Phone: 954.541.8000

Executives

Name Title Contact Details

Similar Companies

Synca Marketing Inc

Synca Marketing Inc is a Le Gardeur, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ilshin America

Ilshin America is a Hialeah, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Panthera Dental

Headquartered in Quebec City, Canada, Panthera Dental is a world leader in CAD/CAM prosthetic implant solutions and dental sleep appliances. The rapid growth of the company is based on the values that are very dear to us, namely highly attentive customer care, quality products, as well as innovation, and on its collaboration with many key opinion leaders in the dentistry field. Both a pioneer and a leader, Panthera Dental has successfully combined creativity, science and know-how to develop its proprietary innovative technology and is now able to offer next-generation products to the dental industry worldwide.

Del Global Technologies Corporation

Del Global Technologies Corp. (Del Global) is engaged in developing, manufacturing and marketing medical and dental imaging systems, and power conversion subsystems and components worldwide. The CompanyÍs products include stationary and portable medical

Glaukos

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world`s leading causes of blindness. Glaukos has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. The company launched the iStent Trabecular Micro-Bypass Stent, its first MIGS device, in the United States in 2012. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. Glaukos believes the iStent is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, the company completed an initial public offering and its shares are now traded on the New York Stock Exchange under the ticker symbol "GKOS". Founded in 1998, Glaukos is based in San Clemente, California.